{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T12:06:09Z","timestamp":1790165169032,"version":"4.1.0"},"reference-count":22,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T00:00:00Z","timestamp":1769472000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Prostate International"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.prnil.2026.01.004","type":"journal-article","created":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T07:19:01Z","timestamp":1770016741000},"page":"230-235","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Testosterone dynamics and oncologic safety in biochemically recurrent prostate cancer: An analysis of intermittent androgen deprivation therapy schedules"],"prefix":"10.1016","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-1813-9736","authenticated-orcid":false,"given":"Jeong Hyun","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung Un","family":"Bang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byung Ha","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7303-6256","authenticated-orcid":false,"given":"Kyo Chul","family":"Koo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7836-1998","authenticated-orcid":false,"given":"Tae Jin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.prnil.2026.01.004_bib1","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.eururo.2015.10.007","article-title":"Intermittent versus continuous androgen deprivation therapy in patients with relapsing or locally advanced prostate cancer: a phase 3b randomised study (ICELAND)","volume":"69","author":"Schulman","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.prnil.2026.01.004_bib2","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.prnil.2024.11.005","article-title":"Clinical significance of primary tumor progression in metastatic hormone-sensitive prostate cancer","volume":"13","author":"Yamada","year":"2025","journal-title":"Prostate Int"},{"key":"10.1016\/j.prnil.2026.01.004_bib3","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.juro.2017.07.078","article-title":"Testosterone responders to continuous androgen deprivation therapy show considerable variations in testosterone levels on followup: implications for clinical practice","volume":"199","author":"Sayyid","year":"2018","journal-title":"J Urol"},{"key":"10.1016\/j.prnil.2026.01.004_bib4","doi-asserted-by":"crossref","first-page":"115","DOI":"10.14310\/horm.2002.1727","article-title":"Adverse effects of androgen deprivation therapy in patients with prostate cancer: focus on metabolic complications","volume":"16","author":"Tzortzis","year":"2017","journal-title":"Hormones (Basel)"},{"key":"10.1016\/j.prnil.2026.01.004_bib5","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.juro.2017.05.072","article-title":"Clinical outcomes and testosterone levels following continuous androgen deprivation in patients with relapsing or locally advanced prostate cancer: a post hoc analysis of the ICELAND study","volume":"198","author":"Tombal","year":"2017","journal-title":"J Urol"},{"key":"10.1016\/j.prnil.2026.01.004_bib6","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.prnil.2024.03.003","article-title":"The impact of obesity and sexual behavior on prostate cancer risk is mediated by testosterone levels: a mendelian randomization study and mediation analysis","volume":"12","author":"Di","year":"2024","journal-title":"Prostate Int"},{"key":"10.1016\/j.prnil.2026.01.004_bib7","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s11934-013-0325-x","article-title":"Intermittent versus continuous androgen deprivation therapy in advanced prostate cancer","volume":"14","author":"Klotz","year":"2013","journal-title":"Curr Urol Rep"},{"key":"10.1016\/j.prnil.2026.01.004_bib8","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.eururo.2012.07.040","article-title":"Advanced prostate cancer treated with intermittent or continuous androgen deprivation in the randomised FinnProstate study VII: quality of life and adverse effects","volume":"63","author":"Salonen","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.prnil.2026.01.004_bib9","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/pcan.2012.12","article-title":"Testosterone recovery in the off-treatment time in prostate cancer patients undergoing intermittent androgen deprivation therapy","volume":"15","author":"Tunn","year":"2012","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.prnil.2026.01.004_bib10","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1056\/NEJMoa1201546","article-title":"Intermittent androgen suppression for rising PSA level after radiotherapy","volume":"367","author":"Crook","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.prnil.2026.01.004_bib11","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/j.ijrobp.2023.12.022","article-title":"Prostate-specific antigen response to androgen deprivation therapy in the neoadjuvant setting for high-risk prostate adenocarcinoma (PIRANHA): pooled analysis of two randomized clinical trials","volume":"119","author":"Nikitas","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prnil.2026.01.004_bib12","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1200\/JCO.2014.58.2973","article-title":"Nadir testosterone within first year of androgen-deprivation therapy (ADT) predicts for time to castration-resistant progression: a secondary analysis of the PR-7 trial of intermittent versus continuous ADT","volume":"33","author":"Klotz","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.prnil.2026.01.004_bib13","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1200\/JCO.22.00970","article-title":"Sequencing of androgen-deprivation therapy of short duration with radiotherapy for nonmetastatic prostate cancer (SANDSTORM): a pooled analysis of 12 randomized trials","volume":"41","author":"Ma","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.prnil.2026.01.004_bib14","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/S1470-2045(16)00107-8","article-title":"Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial","volume":"17","author":"Duchesne","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.prnil.2026.01.004_bib15","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1111\/andr.13107","article-title":"Differences in sex hormone recovery profile after cessation of 12-week gonadotropin-releasing hormone antagonist versus agonist therapy","volume":"10","author":"Sasaki","year":"2022","journal-title":"Andrology"},{"key":"10.1016\/j.prnil.2026.01.004_bib16","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.clgc.2023.08.008","article-title":"Intermittent versus continuous androgen deprivation therapy for biochemical progression after primary therapy in hormone-sensitive nonmetastatic prostate cancer: comparative analysis in terms of CRPC-M0 progression","volume":"22","author":"Salciccia","year":"2024","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.prnil.2026.01.004_bib17","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.beem.2008.01.003","article-title":"Intracrine androgen metabolism in prostate cancer progression: mechanisms of castration resistance and therapeutic implications","volume":"22","author":"Mostaghel","year":"2008","journal-title":"Best Pract Res Clin Endocrinol Metabol"},{"key":"10.1016\/j.prnil.2026.01.004_bib18","doi-asserted-by":"crossref","first-page":"46","DOI":"10.3816\/CGC.2008.n.008","article-title":"Quality of life, morbidity, and mortality results of a prospective phase II study of intermittent androgen suppression for men with evidence of prostate-specific antigen relapse after radiation therapy for locally advanced prostate cancer","volume":"6","author":"Bruchovsky","year":"2008","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.prnil.2026.01.004_bib19","doi-asserted-by":"crossref","first-page":"416","DOI":"10.4111\/icu.20250147","article-title":"Establishing consensus recommendations for metastatic hormone-sensitive prostate cancer in South Korea: a modified Delphi study","volume":"66","author":"Joung","year":"2025","journal-title":"Investig Clin Urol"},{"key":"10.1016\/j.prnil.2026.01.004_bib20","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1002\/pon.1401","article-title":"Cognitive and mood changes in men undergoing intermittent combined androgen blockade for non-metastatic prostate cancer","volume":"18","author":"Cherrier","year":"2009","journal-title":"Psychooncology"},{"key":"10.1016\/j.prnil.2026.01.004_bib21","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.prnil.2024.07.004","article-title":"Cardiovascular risks of Asian patients on androgen-receptor-targeted agents for prostate cancer: a systematic review and meta-analysis","volume":"12","author":"Kyaw","year":"2024","journal-title":"Prostate Int"},{"key":"10.1016\/j.prnil.2026.01.004_bib22","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa032975","article-title":"Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy","volume":"351","author":"D\u2019Amico","year":"2004","journal-title":"N Engl J Med"}],"container-title":["Prostate International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2287888226000048?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2287888226000048?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T11:46:59Z","timestamp":1790164019000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2287888226000048"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S2287888226000048"],"URL":"https:\/\/doi.org\/10.1016\/j.prnil.2026.01.004","relation":{},"ISSN":["2287-8882"],"issn-type":[{"value":"2287-8882","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Testosterone dynamics and oncologic safety in biochemically recurrent prostate cancer: An analysis of intermittent androgen deprivation therapy schedules","name":"articletitle","label":"Article Title"},{"value":"Prostate International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prnil.2026.01.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Asian Pacific Prostate Society. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}